Saturday 10 October 2026 Export all MRK data to Excel Powerpack

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.60 3.22 +2.26%
Market cap
$351.3B
P/E
116×
Fwd P/E
53.9×
Dividend yield
2.34%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100

Merck & Co., Inc. (MRK) EV/FCF

Alert me on EV/FCF

As of 9 October 2026, Merck & Co., Inc. (MRK) trades at a EV/FCF of 25.1×. Over the past ten years it has ranged from 12.3× (May 2025) to 532× (December 2020); the current reading is higher than 50% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 23.9× 58.70%
FY2024 15.1× (56.11%)
FY2023 34.3× 70.02%
FY2022 20.2× (19.10%)
FY2021 25.0× (62.95%)
FY2020 67.4× 58.19%
FY2019 42.6× 72.43%
FY2018 24.7× (29.26%)
FY2017 34.9× 81.34%
FY2016 19.3× 42.26%

Quarterly newest first

Period EV/FCF Change
Jun 2026 22.5× (6.15%)
Mar 2026 24.0× 0.24%
Dec 2025 23.9× 34.98%
Sep 2025 17.7× 16.41%
42 more quarters

Against its own ten years

Low 12.3× High 532×
Ten-year median 25.1×
Current reading's percentile 50

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on MRK